Maternal antenatal methylxanthine (including caffeine) treatment for improving preterm outcomes

Simple item page
dc.check.date2020-02-25
dc.check.infoAccess to this article is restricted until 12 months after publication by request of the publisher.en
dc.contributor.authorRoehr, Charles Christoph C.
dc.contributor.authorBanerjee, Rupjani
dc.contributor.authorAlarcon-Allen, Ana
dc.contributor.authorDempsey, Eugene M.
dc.contributor.funderNational Institute for Health Researchen
dc.date.accessioned2019-05-29T11:28:49Z
dc.date.available2019-05-29T11:28:49Z
dc.date.issued2019-02-25
dc.date.updated2019-05-29T11:15:03Z
dc.description.abstractThis is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To review and summarise the existing evidence of the relationship between maternal methylxanthine (including caffeine) consumption (or by any other method of administration) versus no intervention, placebo or a different methylxanthine, before birth with the intention to influence outcomes in preterm newborns, with particular focus on cardiorespiratory adaptation at birth and long-term neurodevelopmental outcomes.en
dc.description.sponsorshipNational Institute for Health Research (Cochrane Infrastructure funding to Cochrane Pregnancy and Childbirth)en
dc.description.statusPeer revieweden
dc.description.versionPublished Versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.articleidCD013275en
dc.identifier.citationRoehr, C. C. C., Banerjee, R., Alarcon-Allen, A. and Dempsey, E. (2019) 'Maternal antenatal methylxanthine (including caffeine) treatment for improving preterm outcomes', Cochrane Database of Systematic Reviews, Issue 2, CD013275 (9pp). doi: 10.1002/14651858.CD013275en
dc.identifier.doi10.1002/14651858.CD013275en
dc.identifier.eissn1469-493X
dc.identifier.endpage9en
dc.identifier.issn1465-1858
dc.identifier.issued2en
dc.identifier.journaltitleCochrane Database of Systematic Reviewsen
dc.identifier.startpage1en
dc.identifier.urihttps://hdl.handle.net/10468/7998
dc.language.isoenen
dc.publisherJohn Wiley & Sons, Ltd. on behalf of the Cochrane Collaborationen
dc.relation.urihttps://doi.org//10.1002/14651858.CD013275
dc.rights© 2019, the Cochrane Collaboration. Published by John Wiley & Sons, Ltd. All rights reserved.en
dc.subjectMethylxanthineen
dc.subjectCaffeineen
dc.subjectCardiorespiratory adaptationen
dc.subjectNeurodevelopmental outcomesen
dc.titleMaternal antenatal methylxanthine (including caffeine) treatment for improving preterm outcomesen
dc.typeOtheren
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Roehr_et_al-2019-Cochrane_Database_of_Systematic_Reviews.pdf
Size:
182.45 KB
Format:
Adobe Portable Document Format
Description:
Published Version
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Paediatrics and Child Health - Journal Articles